Compare STRO & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRO | BNY |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 245.0M |
| IPO Year | 2018 | N/A |
| Metric | STRO | BNY |
|---|---|---|
| Price | $9.73 | $10.17 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 110.8K | 52.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,646,000.00 | N/A |
| Revenue This Year | $62.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $8.60 |
| 52 Week High | $24.80 | $10.80 |
| Indicator | STRO | BNY |
|---|---|---|
| Relative Strength Index (RSI) | 88.38 | 48.94 |
| Support Level | $7.88 | $10.20 |
| Resistance Level | $9.38 | $10.27 |
| Average True Range (ATR) | 0.63 | 0.08 |
| MACD | 0.73 | 0.00 |
| Stochastic Oscillator | 97.12 | 36.96 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.